Sitagliptinphosphate , 98% , 654671-78-0

Synonym(s):
7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate;MK-0431;Sitagliptin phosphate monohydrate

CAS NO.：654671-78-0

Empirical Formula: C16H15F6N5O.H3PO4

Molecular Weight: 505.31

MDL number: MFCD09952339

EINECS: 1806241-263-5

PRODUCT Properties

• Melting point: 202-204°C
• storage temp.: -20°C Freezer
• solubility: Methanol (Slightly, Heated), Water (Sparingly, Sonicated)
• form: Solid
• color: White to Off-White
• InChI: InChI=1S/C16H15F6N5O.H3O4P/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4)
• InChIKey: IQFYVLUXQXSJJN-UHFFFAOYSA-N
• SMILES: C(C1=CC(F)=C(F)C=C1F)C(N)CC(=O)N1CCN2C(C(F)(F)F)=NN=C2C1.P(O)(O)(O)=O

Description and Uses

Sitagliptin is the first novel dipeptidyl peptidase IV inhibitor from Merck for the treatment of type 2 diabetes without weight gain and the incidence of hypoglycemia was similar to placebo. Sitagliptin acts by enhancing the body’s incretin system, which helps to regulate glucose by affecting β and α cells in the pancreas.

A trizolopyrazine dipeptidyl peptidase IV inhibitor. It has recently been approved for the therapy of type II diabetes.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338